Recently, the State Drug Administration approved the marketing of bartolizumab injections declared by Jiaxi Holdings Co., Ltd. to be used in combination with conventional therapeutic drugs to treat adult systemic myasthenia gravis patients with positive anti-acetylcholine receptor antibodies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.